Maynard Um
-
-
-
-
-
-
-
Ascendis reports sustained growth in achondroplasia trial subgroup
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $262 at BofA Securities
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $324 at Evercore ISI
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Misses Q4 EPS by 40c
-
-
-
-
-
-
-
4Q25/2026 Biotech Earnings Preview: RBC
-
-
-
-
-
-
-
Ascendis Pharma publishes pivotal trial results for achondroplasia drug
-
-
-
-
-
-
-
Cantor Fitzgerald Raises Ascendis Pharma (ASND) PT to $254, Sees Steady New Patient Adds
-
431,646 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

